Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : A network meta-analysis.
Young Ho LeeGwan Gyu SongPublished in: Zeitschrift fur Rheumatologie (2021)
No significant difference in ACR20 response rates and SAEs were detected between infliximab biosimilars and the originator in the investigated study populations.
Keyphrases